Nanjing University

About: Nanjing University is a education organization based out in Nanjing, China. It is known for research contribution in the topics: Catalysis & Adsorption. The organization has 85961 authors who have published 105504 publications receiving 2289036 citations. The organization is also known as: NJU & Nanking University.

Geomorphic and geologic controls of geohazards induced by Nepal’s 2015 Gorkha earthquake

Abstract: The Gorkha earthquake (M 7.8) on 25 April 2015 and later aftershocks struck South Asia, killing ~9,000 and damaging a large region. Supported by a large campaign of responsive satellite data acquisitions over the earthquake disaster zone, our team undertook a satellite image survey of the earthquakes’ induced geohazards in Nepal and China and an assessment of the geomorphic, tectonic, and lithologic controls on quake-induced landslides. Timely analysis and communication aided response and recovery and informed decision makers. We mapped 4,312 co-seismic and post-seismic landslides. We also surveyed 491 glacier lakes for earthquake damage, but found only 9 landslide-impacted lakes and no visible satellite evidence of outbursts. Landslide densities correlate with slope, peak ground acceleration, surface downdrop, and specific metamorphic lithologies and large plutonic intrusions.

Global projections of future urban land expansion under shared socioeconomic pathways

Abstract: Despite its small land coverage, urban land and its expansion have exhibited profound impacts on global environments. Here, we present the scenario projections of global urban land expansion under the framework of the shared socioeconomic pathways (SSPs). Our projections feature a fine spatial resolution of 1 km to preserve spatial details. The projections reveal that although global urban land continues to expand rapidly before the 2040s, China and many other Asian countries are expected to encounter substantial pressure from urban population decline after the 2050s. Approximately 50–63% of the newly expanded urban land is expected to occur on current croplands. Global crop production will decline by approximately 1–4%, corresponding to the annual food needs for a certain crop of 122–1389 million people. These findings stress the importance of governing urban land development as a key measure to mitigate its negative impacts on food production. Shared socioeconomic pathways (SSPs) is a crucial scenario describing the potential of future socio-economic development. The authors here investigate long-term effects of various government policies suggested by different SSPs on urban land and reveal the impact of future urban expansion on other land and food production.

Polyaniline/Au composite hollow spheres: synthesis, characterization, and application to the detection of dopamine.

Abstract: Polyaniline (PANI)/Au composite hollow spheres were successfully synthesized using polystyrene/sulfonated polystyrene core/shell gel particle templates. The PANI shell thickness and the number of Au nanoparticles decorating the PANI could be controlled effectively by adjusting the experimental conditions. The morphology, composition, and optical properties of the resulting products were characterized by scanning electron microscopy, transmission electron microscopy, X-ray diffraction, thermogravimetric analysis, X-ray photoelectron spectroscopy, Fourier transform infrared spectroscopy, and ultraviolet-visible absorption spectra. It was found that the electrical conductivity of the PANI/Au composite hollow spheres was more than 3 times higher than that of the pure PANI hollow spheres. Furthermore, PANI/Au composites were immobilized on the surface of a glassy carbon electrode (GCE) and applied to construct a sensor. The obtained PANI/Au-modified GCEs showed one pair of redox peaks and high catalytic activity for the oxidation of dopamine. The possible formation mechanism of the PANI/Au composite hollow spheres was also discussed.

Semi-Supervised Dimensionality Reduction.

Abstract: Dimensionality reduction is among the keys in mining highdimensional data. This paper studies semi-supervised dimensionality reduction. In this setting, besides abundant unlabeled examples, domain knowledge in the form of pairwise constraints are available, which specifies whether a pair of instances belong to the same class (must-link constraints) or different classes (cannot-link constraints). We propose the SSDR algorithm, which can preserve the intrinsic structure of the unlabeled data as well as both the must-link and cannot-link constraints defined on the labeled examples in the projected low-dimensional space. The SSDR algorithm is efficient and has a closed form solution. Experiments on a broad range of data sets show that SSDR is superior to many established dimensionality reduction methods.

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.

Abstract: Summary Background China has a high burden of hepatocellular carcinoma, and hepatitis B virus (HBV) infection is the main causative factor. Patients with hepatocellular carcinoma have a poor prognosis and a substantial unmet clinical need. The phase 2–3 ORIENT-32 study aimed to assess sintilimab (a PD-1 inhibitor) plus IBI305, a bevacizumab biosimilar, versus sorafenib as a first-line treatment for unresectable HBV-associated hepatocellular carcinoma. Methods This randomised, open-label, phase 2–3 study was done at 50 clinical sites in China. Patients aged 18 years or older with histologically or cytologically diagnosed or clinically confirmed unresectable or metastatic hepatocellular carcinoma, no previous systemic treatment, and a baseline Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 were eligible for inclusion. In the phase 2 part of the study, patients received intravenous sintilimab (200 mg every 3 weeks) plus intravenous IBI305 (15 mg/kg every 3 weeks). In the phase 3 part, patients were randomly assigned (2:1) to receive either sintilimab plus IBI305 (sintilimab–bevacizumab biosimilar group) or sorafenib (400 mg orally twice daily; sorafenib group), until disease progression or unacceptable toxicity. Randomisation was done using permuted block randomisation, with a block size of six, via an interactive web response system, and stratified by macrovascular invasion or extrahepatic metastasis, baseline α-fetoprotein, and ECOG performance status. The primary endpoint of the phase 2 part of the study was safety, assessed in all patients who received at least one dose of study drug. The co-primary endpoints of the phase 3 part of the study were overall survival and independent radiological review committee (IRRC)-assessed progression-free survival according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 in the intention-to-treat population. The study is registered with ClinicalTrials.gov , NCT03794440 . The study is closed to new participants and follow-up is ongoing for long-term outcomes. Findings Between Feb 11, 2019 and Jan 15, 2020, we enrolled 595 patients: 24 were enrolled directly into the phase 2 safety run-in and 571 were randomly assigned to sintilimab–bevacizumab biosimilar (n=380) or sorafenib (n=191). In the phase 2 part of the trial, 24 patients received at least one dose of the study drug, with an objective response rate of 25·0% (95% CI 9·8–46·7). Based on the preliminary safety and activity data of the phase 2 part, in which grade 3 or worse treatment-related adverse events occurred in seven (29%) of 24 patients, the randomised phase 3 part was started. At data cutoff (Aug 15, 2020), the median follow-up was 10·0 months (IQR 8·5–11·7) in the sintilimab–bevacizumab biosimilar group and 10·0 months (8·4–11·7) in the sorafenib group. Patients in the sintilimab–bevacizumab biosimilar group had a significantly longer IRRC-assessed median progression-free survival (4·6 months [95% CI 4·1–5·7]) than did patients in the sorafenib group (2·8 months [2·7–3·2]; stratified hazard ratio [HR] 0·56, 95% CI 0·46–0·70; p Interpretation Sintilimab plus IBI305 showed a significant overall survival and progression-free survival benefit versus sorafenib in the first-line setting for Chinese patients with unresectable, HBV-associated hepatocellular carcinoma, with an acceptable safety profile. This combination regimen could provide a novel treatment option for such patients. Funding Innovent Biologics. Translation For the Chinese translation of the abstract see Supplementary Materials section.